keyword
MENU ▼
Read by QxMD icon Read
search

Cancer-related Fatigue

keyword
https://www.readbyqxmd.com/read/29036016/exercise-preserves-physical-function-in-prostate-cancer-patients-with-bone-metastases
#1
Daniel A Galvão, Dennis R Taaffe, Nigel Spry, Prue Cormie, David Joseph, Suzanne K Chambers, Raphael Chee, Carolyn Peddle-McIntyre, Nicolas H Hart, Freerk T Baumann, James Denham, Michael Baker, Robert U Newton
PURPOSE: The presence of bone metastases has excluded participation of cancer patients in exercise interventions and is a relative contraindication to supervised exercise in the community setting due to concerns of fragility fracture. We examined the efficacy and safety of a modular multi-modal exercise program in prostate cancer patients with bone metastases. METHODS: Between 2012 and 2015, 57 prostate cancer patients (70.0±8.4 years; BMI 28.7±4.0 kg/m) with bone metastases (pelvis 75...
October 14, 2017: Medicine and Science in Sports and Exercise
https://www.readbyqxmd.com/read/29035593/the-impact-of-body-mass-index-and-waist-circumference-on-health-related-quality-of-life-among-colorectal-cancer-survivors-results-from-the-profiles-registry
#2
Pauline A J Vissers, Renata B Martucci, Floortje Mols, Martijn J L Bours, Renate M Winkels, Ellen Kampman, Matty P Weijenberg, Lonneke V van de Poll-Franse, Sandra Beijer
BACKGROUND: We aimed to assess the association of waist circumference (WC) and body mass index (BMI) with health-related quality of life (HRQL) among colorectal cancer (CRC) survivors. METHODS: CRC survivors diagnosed between 2000 and 2009 completed questionnaires in August 2013 (with self-reported weight, height, and self-assessed WC) and January 2014 (with HRQL using the EORTC-QLQ-C30). Clinical characteristics were retrieved from the Netherlands Cancer Registry...
October 16, 2017: Nutrition and Cancer
https://www.readbyqxmd.com/read/29034740/efficacy-and-safety-of-the-traditional-herbal-medicine-gamiguibi-tang-in-patients-with-cancer-related-sleep-disturbance-a-prospective-randomized-wait-list-controlled-pilot-study
#3
Jee Young Lee, Hye Kyung Oh, Han Sung Ryu, Sung Soo Yoon, Wankyu Eo, Seong Woo Yoon
BACKGROUND: Sleep disturbance is the second most bothersome symptom in patients with cancer, and it can significantly impair their quality of life. The aim of this study was to investigate the efficacy and safety of the traditional herbal medicine Gamiguibi-tang (GGBT) in patients with cancer-related sleep disturbance. METHODS: We conducted a prospective, randomized, wait-list-controlled, open-label pilot clinical trial on cancer-related sleep disturbance. Patients with cancer experiencing poor sleep quality with a Pittsburgh Sleep Quality Index of at least 6 were randomly assigned to the GGBT and wait-list groups to receive GGBT and conventional care, respectively, for 2 weeks...
October 1, 2017: Integrative Cancer Therapies
https://www.readbyqxmd.com/read/29033099/custirsen-ogx-011-combined-with-cabazitaxel-and-prednisone-versus-cabazitaxel-and-prednisone-alone-in-patients-with-metastatic-castration-resistant-prostate-cancer-previously-treated-with-docetaxel-affinity-a-randomised-open-label-international-phase-3-trial
#4
Tomasz M Beer, Sebastien J Hotte, Fred Saad, Boris Alekseev, Vsevolod Matveev, Aude Fléchon, Gwenaelle Gravis, Florence Joly, Kim N Chi, Zafar Malik, Brent Blumenstein, Patricia S Stewart, Cindy A Jacobs, Karim Fizazi
BACKGROUND: Docetaxel and cabazitaxel improve overall survival compared with mitoxantrone in patients with metastatic castration-resistant prostate cancer. Custirsen (OGX011) is a second generation highly specific antisense oligonucleotide that inhibits the production of clusterin, an antiapoptotic protein that is upregulated in response to chemotherapy and that confers treatment resistance. We aimed to assess whether custirsen in combination with cabazitaxel and prednisone increases overall survival in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel...
October 9, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/29031319/predictors-of-health-related-quality-of-life-in-korean-prostate-cancer-patients-receiving-androgen-deprivation-therapy
#5
Soo Hyun Kim, Do Hwan Seong, Sang Min Yoon, Young Deuk Choi, Eunju Choi, Hosook Song
PURPOSE: We aimed to examine the level of psychological distress, fatigue, and health-related quality of life (HRQOL) and identify HRQOL predictors in men with prostate cancer receiving androgen deprivation therapy (ADT). METHODS: Using a cross-sectional design, we recruited 161 men with prostate cancer receiving ADT (mean age, 73 years) at two university-based hospitals in South Korea. Participants completed a self-reported questionnaire. Measures included the Hospital Anxiety and Depression Scale (HADS), the Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) subscale, and the Functional Assessment of Cancer Therapy-Prostate (FACT-P)...
October 2017: European Journal of Oncology Nursing: the Official Journal of European Oncology Nursing Society
https://www.readbyqxmd.com/read/28994209/identifying-patterns-of-adaptation-in-breast-cancer-patients-with-cancer-related-fatigue-using-response-shift-analyses-at-subgroup-level
#6
Maxime Salmon, Myriam Blanchin, Christine Rotonda, Francis Guillemin, Véronique Sébille
Fatigue is the most prevalent symptom in breast cancer. It might be perceived differently among patients over time as a consequence of the differing patients' adaptation and psychological adjustment to their cancer experience which can be related to response shift (RS). RS analyses can provide important insights on patients' adaptation to cancer but it is usually assumed that RS occurs in the same way in all individuals which is unrealistic. This study aimed to identify patients' subgroups in which different RS effects on self-reported fatigue could occur over time using a combination of methods for manifest and latent variables...
October 10, 2017: Cancer Medicine
https://www.readbyqxmd.com/read/28992856/cancer-related-fatigue-in-cancer-survivorship
#7
REVIEW
Chidinma C Ebede, Yongchang Jang, Carmen P Escalante
Cancer-related fatigue (CRF) significantly interferes with usual functioning because of the distressing sense of physical, emotional, and cognitive exhaustion. Assessment of CRF is important and should be performed during the initial cancer diagnosis, throughout cancer treatment, and after treatment using a fatigue scoring scale (mild-severe). The general approach to CRF management applies to cancer survivors at all fatigue levels and includes education, counseling, and other strategies. Nonpharmacologic interventions include psychosocial interventions, exercise, yoga, physically based therapy, dietary management, and sleep therapy...
November 2017: Medical Clinics of North America
https://www.readbyqxmd.com/read/28992218/long-term-consequences-of-renal-insufficiency-in-children-lessons-learned-from-the-dutch-leric-study
#8
Jaap W Groothoff, Martin Offringa, Martha Grootenhuis, Kitty J Jager
Few data exist on the prospects in adulthood for children on chronic renal replacement therapy (RRT). This article summarizes the results of a comprehensive Dutch long-term follow-up study performed in 2000 and 2010 of patients with RRT onset at age <15 years between 1972 and 1992. After a median of 25.5 RRT years, patients had stayed 23% of RRT time on dialysis. We observed a 30 times greater mortality risk compared with age-matched peers with cardiovascular disease (CVD) as the main cause of death during 1972-2000 and infections during 2000-10...
July 7, 2017: Nephrology, Dialysis, Transplantation
https://www.readbyqxmd.com/read/28990511/sunitinib-in-the-treatment-of-thyroid-cancer
#9
Ferrari Silvia Martinaa, Centanni Marco, Virili Camilla, Miccoli Mario, Ferrari Paola, Ruffilli Ilaria, Ragusa Francesca, Antonelli Alessandro, Fallahi Poupak
BACKGROUND: Sunitinib (SU11248) is an oral, small-molecule, multi-targeted tyrosine kinase inhibitor (TKI), that inhibits receptors for platelet-derived growth factor (PDGF-Rs) and vascular endothelial growth factor receptors (VEGFRs), c-KIT, fms-related tyrosine kinase 3 (FLT3) and RET. The concurrent inhibition of these pathways reduces tumor vascularization and causes cancer cell apoptosis, inducing a tumor shrinkage. Sunitinib is approved for the treatment of imatinib-resistant gastrointestinal stromal tumor (GIST), renal carcinoma, and pancreatic neuroendocrine tumors...
October 6, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28988662/factors-associated-with-fatigue-in-prostate-cancer-pc-patients-undergoing-external-beam-radiation-therapy-ebrt
#10
Hann-Hsiang Chao, Abigail Doucette, David M Raizen, Neha Vapiwala
PURPOSE: Fatigue is a common adverse effect among cancer patients undergoing external beam radiation therapy (EBRT), yet the underlying disease- and treatment-related factors influencing its development are poorly understood. We hypothesized that clinical, demographic, and treatment-related factors differentially affect fatigue and aimed to better characterize variables related to fatigue development in prostate cancer (PC) patients during EBRT. METHODS AND MATERIALS: We identified a cohort of 681 patients with nonmetastatic PC undergoing a 6- to 9-week EBRT course...
September 8, 2017: Practical Radiation Oncology
https://www.readbyqxmd.com/read/28985915/a-theoretical-framework-to-guide-a-study-exploring-cancer-related-fatigue
#11
Patricia O'Regan, Margaret Landers, Josephine Hegarty
No abstract text is available yet for this article.
October 2017: Applied Nursing Research: ANR
https://www.readbyqxmd.com/read/28983735/cancer-related-loneliness-mediates-the-relationships-between-social-constraints-and-symptoms-among-cancer-patients
#12
Rebecca N Adams, Catherine E Mosher, Joseph G Winger, Rafat Abonour, Kurt Kroenke
Cancer patients have high rates of persistent and disabling symptoms. Evidence suggests that social constraints (e.g., avoidance and criticism) negatively impact symptoms, but pathways linking these variables have yet to be identified. This study examined whether cancer-related loneliness (i.e., feeling socially disconnected related to having cancer) mediated the relationships between social constraints and symptoms (i.e., pain interference, fatigue, sleep disturbance, and cognitive complaints) in patients with various cancers (N = 182)...
October 5, 2017: Journal of Behavioral Medicine
https://www.readbyqxmd.com/read/28983561/difficulties-in-defining-and-measuring-cancer-related-fatigue-reply
#13
Karen M Mustian, Luke J Peppone, Suzanne M Miller
No abstract text is available yet for this article.
October 5, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28983559/difficulties-in-defining-and-measuring-cancer-related-fatigue
#14
Lawrence Berk
No abstract text is available yet for this article.
October 5, 2017: JAMA Oncology
https://www.readbyqxmd.com/read/28972963/a-phase-1-study-of-arq-087-an-oral-pan-fgfr-inhibitor-in-patients-with-advanced-solid-tumours
#15
K P Papadopoulos, B F El-Rayes, A W Tolcher, A Patnaik, D W Rasco, R D Harvey, P M LoRusso, J C Sachdev, G Abbadessa, R E Savage, T Hall, B Schwartz, Y Wang, J Kazakin, W L Shaib
BACKGROUND: ARQ 087 is an orally administered pan-FGFR inhibitor with multi-kinase activity. This Phase 1 study evaluated safety, pharmacokinetics, and pharmacodynamics of ARQ 087 and defined the recommended Phase 2 dose (RP2D). METHODS: Patients with advanced solid tumours received ARQ 087 administered initially at 25 mg every other day and dose-escalated from 25 to 425 mg daily (QD) continuous dosing. FGF19, 21, 23, and serum phosphate were assessed as potential biomarkers of target engagement...
October 3, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28971436/long-term-survival-of-women-with-breast-cancer-overview-supportive-care-needs-assessment-instruments
#16
Parthenopi Ktistaki, Nephely Alevra, Maria Voulgari
INTRODUCTION: Worldwide, breast cancer is the fifth leading cause of cancer death (after lung, stomach, liver and colon cancer), while among women it is first on the list. The incidence of breast cancer has made a dramatic increase since 1970 which is partly interpreted by the modern western life standards. The expected risk of breast cancer throughout a lifespan of an average is 1 in 11 women. The five-year survival rates for breast cancer are at 80% if it has not spread, and only at 40% for the metastatic type of cancer...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28967485/first-line-pembrolizumab-in-cisplatin-ineligible-patients-with-locally-advanced-and-unresectable-or-metastatic-urothelial-cancer-keynote-052-a-multicentre-single-arm-phase-2-study
#17
Arjun V Balar, Daniel Castellano, Peter H O'Donnell, Petros Grivas, Jacqueline Vuky, Thomas Powles, Elizabeth R Plimack, Noah M Hahn, Ronald de Wit, Lei Pang, Mary J Savage, Rodolfo F Perini, Stephen M Keefe, Dean Bajorin, Joaquim Bellmunt
BACKGROUND: More than half of all patients with advanced urothelial cancer cannot receive standard, first-line cisplatin-based chemotherapy because of renal dysfunction, poor performance status, or other comorbidities. We assessed the activity and safety of first-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer. METHODS: In this multicentre, single-arm, phase 2 study (KEYNOTE-052), cisplatin-ineligible patients with advanced urothelial cancer who had not been previously treated with systemic chemotherapy were recruited from 91 academic medical centres in 20 countries...
September 26, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28965272/predictors-of-the-quality-of-life-in-chinese-breast-cancer-survivors
#18
Juan Xia, Zheng Tang, Qinglong Deng, Renren Yang, Jiwei Wang, Jinming Yu
PURPOSE: Little is known about the importance of various factors which impair the quality of life (QOL) in survivors of breast cancer 1 year after diagnosis and over 1 year after diagnosis in China. Hence, the goal of this article is to quantitatively evaluate the factors which play an active role in impairing QOL 1 year after diagnosis and over 1 year after diagnosing survivors. METHODS: A population-based cross-sectional study was conducted at 34 Cancer Recovery Clubs across China from May 2014 to January 2015...
September 30, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28960265/cabozantinib-is-well-tolerated-in-acute-myeloid-leukemia-and-effectively-inhibits-the-resistance-conferring-flt3-tyrosine-kinase-domain-f691-mutation
#19
Amir T Fathi, Traci M Blonquist, Daniela Hernandez, Philip C Amrein, Karen K Ballen, Malgorzata McMasters, David E Avigan, Robin Joyce, Emma K Logan, Gabriela Hobbs, Andrew M Brunner, Christelle Joseph, Ashley M Perry, Meghan Burke, Tanya Behnan, Julia Foster, Meghan K Bergeron, Jenna A Moran, Aura Y Ramos, Tina T Som, Jessica Rae, Kaitlyn M Fishman, Kristin L McGregor, Christine Connolly, Donna S Neuberg, Mark J Levis
BACKGROUND: Cabozantinib, a tyrosine kinase inhibitor of FMS-like tyrosine kinase 3 (FLT3), MET, AXL, vascular endothelial growth factor receptor, and KIT, is approved for use in multiple malignancies. We assessed the safety and tolerability of cabozantinib in AML, given up-regulation of multiple relevant pathways. METHODS: Adults were eligible if they were 18 years old or older with relapsed/refractory AML or if they were 70 years old or older with newly diagnosed AML but were ineligible for conventional therapy...
September 28, 2017: Cancer
https://www.readbyqxmd.com/read/28960263/comparison-of-the-toxicity-profile-of-pd-1-versus-pd-l1-inhibitors-in-non-small-cell-lung-cancer-a-systematic-analysis-of-the-literature
#20
Rathi N Pillai, Madhusmita Behera, Taofeek K Owonikoko, Alice O Kamphorst, Suchita Pakkala, Chandra P Belani, Fadlo R Khuri, Rafi Ahmed, Suresh S Ramalingam
BACKGROUND: Monoclonal antibodies against programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) are effective therapies in patients with non-small cell lung cancer (NSCLC). Herein, the authors performed a systematic review investigating differences in the toxicities of PD-1 and PD-L1 inhibitors. METHODS: An electronic literature search was performed of public databases (MEDLINE, Excerpta Medica dataBASE [EMBASE], and Cochrane) and conference proceedings for trials using PD-1 inhibitors (nivolumab and pembrolizumab) and PD-L1 inhibitors (atezolizumab, durvalumab, and avelumab) in patients with NSCLC...
September 28, 2017: Cancer
keyword
keyword
39571
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"